NCT05361902Active, not recruiting
A First Step Towards Ultra-hypofractionation for Unfavourable Intermediate and High-risk Prostate Cancer
A First Step Towards Ultra-hypofractionation for Unfavourable Intermediate and High-risk Prostate Cancer: a Prospective Safety and Feasibility Study in Patients With Metastatic Prostate Cancer
Source: ClinicalTrials.gov · Last updated 28 Aug 2024
Brief summary (registry, in English)
This study aims to make a first step towards ultra-hypofractionation for high-risk prostate cancer by proving the technical feasibility of margin reduction of the seminal vesicles by combining the intra-fraction fiducial tracking with an online re-planning workflow for each fraction to account for the inter-fraction seminal vesicle motion.
- Status (registry)
- Active, not recruiting
- Study type
- Interventional
- Enrollment
- 35 (actual)
- First submitted
- 19 Apr 2022
- Start date
- 7 Jul 2022
- Primary completion date
- 13 Jun 2024
- Lead sponsor
- Erasmus Medical Center
- Diseases
- Prostate cancer
- NCT number
- NCT05361902
What you commit to
- Study type: Interventional
- Participants enrolled: 35
- From 7 Jul 2022 to the primary completion date, 13 Jun 2024
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Previous pelvic radiotherapy or surgery for prostate cancer (excluding surgery to improve urinary function in benign prostate hyperplasia, i.e. trans-urethral resection of the prostate or prostatectomy according to Millin or Hryntschak)
Other
- According to current clinical protocols at discretion of the treating physician, patients can be excluded in case of, for example, an International Prostate Symptom Score of \>20 or a prostate volume of \>90 milliliters, expecting an unacceptable rise in toxicity rates
Who the study is looking for
- Histologically proven prostate cancer
- Radiologically proven limited metastatic disease
- Referred to the Erasmus MC, after multidisciplinary consensus, for local radiotherapy treatment similar to the STAMPEDE trial
- Willing to and capable of personally filling out online questionnaire
- Signed written informed consent
Age in the registry: 18 years to - · Sex: Male · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Erasmus Medical Centre Coordinator of this site? Confirm its status | Rotterdam | Netherlands | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.